
"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD
The PERSEUS (NCT03710603) and CEPHEUS (NCT03652064) trials both demonstrated improved depth and duration of responses and progression-free survival (PFS) with a quadruplet regimen of daratumumab plus bortezomib (Velcade), lenalidomide (Revlimid), and …